Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Research into the management of MLL

Rob Pieters • 12 Sep 2018
SOHO 2018
Acute Lymphoblastic Leukemia Leukemia Azacitidine Blinatumomab Inotuzumab ozogamicin

Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Rob Pieters, MD, PhD, of Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, discusses current research and drug developments to treat mixed lineage leukemia (MLL) rearranged acute lymphoblastic leukemia (ALL). Prof. Pieters states that numerous epigenetic abnormalities were discovered in MLL rearranged ALL, hence the market for drugs to modify these abnormalities has expanded. He highlights a few drugs that are currently being studied including demethylating agents such as azacitidine as well as monoclonal antibodies blinatumomab and inotuzumab.

More from Rob Pieters

Novel treatment strategies in ALL
Novel treatment strategies in ALL
Nicholas Short et al. • 29 Sep 2022
Updates on the survival rates of MLL treatments
2:28
Updates on the survival rates of MLL treatments
Rob Pieters • 12 Sep 2018
Future directions for MLL therapy
1:26
Future directions for MLL therapy
Rob Pieters • 12 Sep 2018

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals